Goldenseal, a North American root herb sold as a dietary supplement and traditionally used for infections and digestive complaints, has almost no human outcome research. Suggested blood sugar and cholesterol benefits rest mostly on studies of its main compound, berberine, taken in much larger amounts. Repeated human studies show it slows enzymes that clear many prescription drugs, so for people taking regular medications the drug-interaction picture dominates the balance. (Full Review)
| Marker | Target | Why |
|---|---|---|
| HbA1c | 4.0–5.6% | Glucose lowering |
| Fasting glucose | 70–99 mg/dL | Glucose lowering; low-glucose safety check with diabetes drugs |
| ALT | 7–56 U/L | Liver injury safety check |
| Cyclosporine or tacrolimus trough | No established target; transplant team's individual target range | Drug-level safety check |
Cadence: Baseline medication review, ALT, and fasting glucose and HbA1c in diabetes or prediabetes (plus trough level in transplant recipients); fasting glucose weekly for the first 4 weeks in metformin users; trough levels 1–2 weeks after starting or stopping; ALT at 4–8 weeks if use continues beyond a month; HbA1c at 3 months.